Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2023

Metal-Free Direct C-6-H Alkylation of Purines and Purine Nucleosides Enabled by Oxidative Homolysis of 4-Alkyl-1,4-Dihydropyridines at Room Temperature

Qingsong Jiang, ^a Xiguang Liu, ^{*a} Weili Wang, ^a Yiwen Chen ^a and Mingwu Yu ^{*a} ^a School of Chemistry and Materials Science. Ludong University, Yantai 264025, Shandong Province, P. R. China. E-mail: xgliu1986@163.com; ymw2007@163.com

Contents

1.	Substrate scope of DHPs	S2
2.	HRMS about radical trapping experiment with TEMPO and BHT	S3-S5
3.	¹ H NMR and ¹³ C NMR Spectra of the Products	.S6-S49

1. Substrate scope of DHPs

4-Alkyl-1,4-dihydropyridines **2** were synthesized by the methods in previous reports ¹⁻³. And the DHPs were listed below.

Nitrile Hantszch ester were synthesized by the methods in previous reports.⁴

References

- Á. Gutierrez-Bonet, C. Remeur, J. K. Matsui and G. A. Molander, J. Am. Chem. Soc., 2017,
 139, 12251–12258
- Y. Byun, J. Moon, W. An, N. K. Mishra, H. S. Kim, P. Ghosh and I. S. Kim, *J. Org. Chem.*, 2021,
 86, 12247–12256.
- 3. B. Loev and K. M. Snader. J. Org. Chem., 1965, 30,1914-1916.
- 4. W. X. Chen, Z. Liu, J. Q. Tian, J. Li, J. Ma, X. Cheng and G. G. Li, *J. Am. Chem. Soc.*, 2016, **138**, 12312


2. Radical Trapping Experiment with TEMPO

Under ambient atmosphere, substrate $\mathbf{1a}$ (0.26 mmol) and DHP $\mathbf{2a}$ (0.39 mmol, 1.5 equiv.) were dissolved in CH₃CN/H₂O (0.75 mL + 0.75 mL) in a 5 mL vial. (NH₄)₂S₂O₈ (0.39 mmol, 1.5 equiv.) and 2,2,6,6-tetramethyl-1-piperidinoxyl (TEMPO, 0.52 mmol, 2.0 equiv.) were then added to the mixture. Degassing-backfilling with nitrogen for 5 times to remove the oxygen in the system. The system was then reacted at room temperature for 3 h. Then, 5% K₂CO₃ aqueous solution (2 mL) was added to the mixture to adjust pH value. Subsequently, the solution was extracted with ethyl acetate (30 mL). The organic phase was dried over anhydrous MgSO₄, filtered. The crude organic phase was detected by HPLC-HRMS with ESI ion source under positive mode.

The reaction was obviously inhibited, which mean a radical process might be involved. Four different compounds were detected by HRMS, which perhaps were 2a-H, 2a-iPr, TEMPO-iPr, and TEMPO-OH according to the exact mass ([M+H]+). The mechanism about the generation of these compounds was as follow. There is a radical process in the reaction. Firstly, the single electron transfer (SET) oxidation of the DHP 2a by $S_2O_8^{2}$ resulted in the formation of a series of species (pyridine 2a-H, isopropyl radical (i-Pr $^{\bullet}$), etc.) via homolysis. Then, the capturing of isopropyl radical (i-Pr $^{\bullet}$) by TEMPO could form TEMPO-iPr (route a). In fact, we think that the single electron transfer (SET) oxidation of the DHP 2a by $S_2O_8^{2}$ - possibly also resulted in another species (pyridine 2a-iPr, and high active radical (H $^{\bullet}$), which was immediately captured by TEMPO to form TEMPO-OH (route b). Besides, the DHP 2a was also possibly oxidized by TEMPO, resulting in the formation of 2a-iPr and TEMPO-OH (route c).




DHP-TEMPO_20221101154701 #857 RT: 4.64 AV: 1 SB: 96 3.41-3.65 , 5.51-5.78 NL: 3.25E6 T: FTMS + c ESI Full ms [80.0000-1200.0000]






DHP-TEMPO 20221101154701 #1571 RT: 8.60 AV: 1 NL: 7.55E7 T: FTMS + c $\bar{\text{ESI}}$ Full ms [80.0000-1200.0000]









HRMS of 2a-ⁱPr

DHP-TEMPO_20221101154701 #723 RT: 3.94 AV: 1 NL: 4.77E7 T: FTMS + c ESI Full ms [80.0000-1200.0000]





3. ¹ H NMR and ¹³ C NMR Spectra of the Products

 1 H NMR of 6-isopropyl-2′,3′,5′-tri-O-acetyl-nebularine (**3a**) in 500 MHz, CDCl $_3$




¹³C NMR of 6-isopropyl-2',3',5'-tri-*O*-acetyl-nebularine (**3a**) in 125 MHz, CDCl₃







 $^{1}\text{H}-^{13}\text{C}$ COSY of 6-isopropyl-2',3',5'-tri-O-acetyl-nebularine (3a) in CDCl $_{3}$




HMBC of 6-isopropyl-2′,3′,5′-tri-*O*-acetyl-nebularine (**3a**) in CDCl₃




¹H NMR of 9-benzyl-6-isopropyl-9*H*-purine (**3b**) in 500 MHz, CDCl₃




 13 C NMR of 9-benzyl-6-isopropyl-9*H*-purine (**3b**) in 125 MHz, CDCl₃




¹H NMR of 6-isopropyl-9-octyl-9*H*-purine (**3c**) in 500 MHz, CDCl₃




 ^{13}C NMR of 6-isopropyl-9-octyl-9H-purine (3c) in 125 MHz, CDCl $_3$




¹H NMR of 9-(2-bromoethyl)-6-isopropyl-9H-purine (**3d**) in 500 MHz, CDCl₃




 13 C NMR of 9-(2-bromoethyl)-6-isopropyl-9H-purine (3d) in 125 MHz, CDCl₃




¹H NMR of 3-(6-isopropyl-9H-purin-9-yl)propanenitrile (**3e**) in 500 MHz, CDCl₃




¹³C NMR of 3-(6-isopropyl-9H-purin-9-yl)propanenitrile (3e) in 125 MHz, CDCl₃




¹H NMR of ethyl 2-(6-isopropyl-9H-purin-9-yl)acetate (**3f**) in 500 MHz, CDCl₃




 13 C NMR of ethyl 2-(6-isopropyl-9H-purin-9-yl)acetate (3f) in 125 MHz, CDCl $_3$




¹H NMR of 2-(6-isopropyl-9H-purin-9-yl)acetic acid (**3g**) in 500 MHz, CDCl₃




 13 C NMR of 2-(6-isopropyl-9H-purin-9-yl)acetic acid (3g) in 125 MHz, CDCl $_3$




¹H NMR of 1-(6-isopropyl-9H-purin-9-yl)propan-2-one (**3h**) in 500 MHz, CDCl₃





 13 C NMR of 1-(6-isopropyl-9H-purin-9-yl)propan-2-one (**3h**) in 125 MHz, CDCl₃






 ^{13}C NMR of 6-isopropyl-9-(prop-2-yn-1-yl)-9H-purine (3i) in 125 MHz, CDCl $_3$







 ^{13}C NMR of 9-allyl-6-isopropyl-9H-purine (3j) in 125 MHz, CDCl $_3$




¹H NMR of 6-isopropyl-nebularine (**3k**) in 500 MHz, DMSO-d₆




 ^{13}C NMR of 6-isopropyl-nebularine (3k) in 125 MHz, DMSO-d $_6$




¹H NMR of 6-isopropyl-*9H*-purine (**3I**) in 500 MHz, CDCl₃




¹³C NMR of 6-isopropyl-9H-purine (**3I**) in 125 MHz, CDCl₃




 1 H NMR of 6-isopropyl-9-(2′, 3′-O-isoproylidenyl- β -D-ribofuranosyl) purine nucleoside (**3m**) in 500 MHz, CDCl₃




 13 C NMR of 6-isopropyl-9-(2′, 3′-O-isoproylidenyl- β -D-ribofuranosyl) purine nucleoside (**3m**) in 125 MHz, CDCl₃







 13 C NMR of ethyl 2-(6-isopropyl-7*H*-purin-7-yl)acetate (**3n**) in 125 MHz, CDCl $_3$




 $^{1}\text{H-}^{13}\text{COSY}$ of ethyl 2-(6-isopropyl-7*H*-purin-7-yl)acetate (**3n**) in CDCl₃




HMBC of ethyl 2-(6-isopropyl-7H-purin-7-yl)acetate (3n) in CDCl₃




¹H NMR of 3-(6-isopropyl-7*H*-purin-7-yl)propanenitrile (**3o**) in 500 MHz, DMSO-d₆




 13 C NMR of 3-(6-isopropyl-7*H*-purin-7-yl)propanenitrile (**3o**) in 125 MHz, DMSO-d $_6$




¹H NMR of 6-isopropyl-7-(prop-2-yn-1-yl)-7*H*-purine (**3p**) in 500 MHz, CDCl₃




 13 C NMR of 6-isopropyl-7-(prop-2-yn-1-yl)-7H-purine (**3p**) in 125 MHz, CDCl₃




¹H NMR of 9-benzyl-2-chloro-6-isopropyl-*9H*-purine (**3q**) in 500 MHz, CDCl₃



 13 C NMR of 9-benzyl-2-chloro-6-isopropyl-9H-purine (3q) in 125 MHz, CDCl₃




¹H NMR of 9-benzyl-6-isopropyl-2-methoxy-9H-purine (**3r**) in 500 MHz, CDCl₃




¹³C NMR of 9-benzyl-6-isopropyl-2-methoxy-9H-purine (3r) in 125 MHz, CDCl₃







¹H NMR of ethyl 2-(6-(sec-butyl)-9H-purin-9-yl)acetate (4a) in 500 MHz, CDCl₃




 13 C NMR of ethyl 2-(6-(sec-butyl)-9H-purin-9-yl)acetate (4a) in 125 MHz, CDCl $_3$







¹³C NMR of 6-(sec-butyl)-9-(prop-2-yn-1-yl)-9H-purine (4b) in 125 MHz, CDCl₃




¹H NMR of ethyl 2-(6-(pentan-2-yl)-9H-purin-9-yl)acetate (4c) in 500 MHz, CDCl₃




 13 C NMR of ethyl 2-(6-(pentan-2-yl)-9H-purin-9-yl)acetate (4c) in 125 MHz, CDCl $_3$




¹H NMR of 9-benzyl-6-(pentan-2-yl)-9H-purine (4d) in 500 MHz, CDCl₃




¹³C NMR of 9-benzyl-6-(pentan-2-yl)-9H-purine (4d) in 125 MHz, CDCl₃




¹H NMR of ethyl 2-(6-(pentan-3-yl)-9H-purin-9-yl)acetate (**4e**) in 500 MHz, CDCl₃




¹³C NMR of ethyl 2-(6-(pentan-3-yl)-9H-purin-9-yl)acetate (**4e**) in 125 MHz, CDCl₃




 1 H NMR of 6-(pentan-3-yl)-2′,3′,5′-tri-O-acetyl-nebularine (4f) in 500 MHz, CDCl $_3$




 13 C NMR of 6-(pentan-3-yl)-2′,3′,5′-tri-O-acetyl-nebularine (4f) in 125 MHz, CDCl $_3$




¹H NMR of 3-(6-(pentan-3-yl)-7H-purin-7-yl)propanenitrile (4g) in 500 MHz, DMSO-d₆




 13 C NMR of 3-(6-(pentan-3-yl)-7H-purin-7-yl)propanenitrile (4g) in 125 MHz, DMSO-d $_6$







 13 C NMR of ethyl 2-(6-cyclohexyl-9H-purin-9-yl)acetate (4h) in 125 MHz, CDCl $_3$




¹H NMR of 6-cyclohexyl-2',3',5'-tri-*O*-acetyl-nebularine (4i) in 500 MHz, CDCl₃




 13 C NMR of 6-cyclohexyl-2',3',5'-tri-O-acetyl-nebularine (4i) in 125 MHz, CDCl $_3$




¹H NMR of 3-(6-cyclohexyl-9H-purin-9-yl)propanenitrile (4j) in 500 MHz, CDCl₃




 13 C NMR of 3-(6-cyclohexyl-9H-purin-9-yl)propanenitrile (4j) in 125 MHz, CDCl $_3$







 13 C NMR of ethyl 2-(6-(cyclohex-3-en-1-yl)-9H-purin-9-yl)acetate (4k) in 125 MHz, CDCl₃




¹H NMR of 9-benzyl-6-(cyclohex-3-en-1-yl)-9H-purine (4I) in 500 MHz, CDCl₃




 13 C NMR of 9-benzyl-6-(cyclohex-3-en-1-yl)-9H-purine (4I) in 125 MHz, CDCl $_3$




¹H NMR of 3-(6-(cyclohex-3-en-1-yl)-9H-purin-9-yl)propanenitrile (4m) in 500 MHz, CDCl₃




¹³C NMR of 3-(6-(cyclohex-3-en-1-yl)-9H-purin-9-yl)propanenitrile (4m) in 125 MHz, CDCl₃




¹H NMR of 6-t-butyl-2',3',5'-tri-O-acetyl-nebularine (4n) in 500 MHz, CDCl₃




 13 C NMR of 6-t-butyl-2',3',5'-tri-O-acetyl-nebularine (4n) in 125 MHz, CDCl $_3$




¹H NMR of 6-((benzyloxy)methyl)-2',3',5'-tri-*O*-acetyl-nebularine (**4p**) in 500 MHz, CDCl₃




 13 C NMR of 6-((benzyloxy)methyl)-2′,3′,5′-tri-O-acetyl-nebularine (4p) in 125 MHz, CDCl $_3$




¹H NMR of 6-phenoxymethyl-2′,3′,5′-tri-*O*-acetyl-nebularine (**4q**) in 500 MHz, CDCl₃




 13 C NMR of 6-phenoxymethyl-2′,3′,5′-tri-O-acetyl-nebularine (4q) in 125 MHz, CDCl $_3$




 1 H NMR of 6-(phenoxymethyl)-9-(prop-2-yn-1-yl)-9H-purine (4r) in 500 MHz, CDCl $_{3}$




 13 C NMR of 6-(phenoxymethyl)-9-(prop-2-yn-1-yl)-9H-purine (4r) in 125 MHz, CDCl $_3$




¹H NMR of 6-((1,3-dioxoisoindolin-2-yl)methyl)-2',3',5'-tri-*O*-acetyl-nebularine (**4s**) in 500 MHz




 13 C NMR of 6-((1,3-dioxoisoindolin-2-yl)methyl)-2',3',5'-tri-O-acetyl-nebularine (4s) in 125 MHz




¹H NMR of ethyl 2-(6-benzyl-9H-purin-9-yl)acetate (4t) in 500 MHz, CDCl₃




 13 C NMR of ethyl 2-(6-benzyl-9H-purin-9-yl)acetate (4t) in 125 MHz, CDCl $_3$




¹H NMR of 6-cyclopentyl-nebularine (**6-CPN**) in 500 MHz, CDCl₃







13 C NMR of 6-cyclopentyl-nebularine (**6-CPN**) in 125 MHz, CDCl₃




 1 H NMR of 6-((benzyloxy)methyl)-2′,3′,5′-tri-O-acetyl-nebularine (Neb-OBn) in 500 MHz, CDCl $_3$



 13 C NMR of 6-((benzyloxy)methyl)-2′,3′,5′-tri-O-acetyl-nebularine (Neb-OBn) in 125 MHz, CDCl₃





 ^{13}C NMR of 6-hydroxymethyl-nebularine (**6-HOMN**) in 125 MHz, CD₃OD

